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Paget’s disease of bone (PDB) is a common disease
characterized by osteoclast activation that leads
to various skeletal complications. Susceptibility to
PDB is mediated by a common variant at the
optineurin (OPTN) locus, which is associated with
reduced levels of mRNA. However, it is unclear how
this leads to the development of PDB. Here, we
show that OPTN acts as a negative regulator of oste-
oclast differentiation in vitro and that mice with a
loss-of-function mutation in Optn have increased
osteoclast activity and bone turnover. Osteoclasts
derived from Optn mutant mice have an increase in
NF-kB activation and a reduction in interferon beta
expression in response to RANKL when compared
to wild-type mice. These studies identify OPTN as
a regulator of bone resorption and are consistent
with a model whereby genetically determined reduc-
tions in OPTN expression predispose to PDB by
enhancing osteoclast differentiation.INTRODUCTION
Paget’s disease of bone (PDB) is a common skeletal disorder
characterized by osteoclast activation, which provokes
increased but disorganized bone turnover, leading to patholog-
ical fractures, bone deformity, and bone pain. The disease has
a strong genetic component, but the genes responsible have
not been fully characterized. The most important predisposing
gene is SQSTM1, which is mutated in 10% of patients with
the disease. The SQSTM1 causal mutations increase osteoclas-
togenesis by enhancing receptor activator of nuclear factor
kappa B (NF-kB) (RANK) signaling in osteoclasts and their pre-
cursors (Cavey et al., 2006; Daroszewska et al., 2011; Hiruma1096 Cell Reports 13, 1096–1102, November 10, 2015 ª2015 The Auet al., 2008). Linkage studies in families (Lucas et al., 2008)
coupled with genome-wide association studies (GWAS) (Alba-
gha et al., 2010, 2011) have identified a strong susceptibility
locus for PDB at the OPTN locus on chromosome 10p13. The
OPTN gene encodes optineurin, a ubiquitously expressed cyto-
plasmic protein involved in many cellular processes including
regulation of NF-kB signaling (Zhu et al., 2007), autophagy,
and innate immunity (Wild et al., 2011), but the role of optineurin
in bonemetabolism is unknown. Here, we investigated the role of
OPTN in regulating bone turnover and evaluated the molecular
mechanisms by which variants at the OPTN locus predispose
to PDB.
RESULTS AND DISCUSSION
Reduced Expression of OPTN Predisposes to PDB
In order to identify disease-causingmutations in theOPTN locus,
we conducted mutation screening of the coding exons of OPTN
in 200 PDB patients, but results showed no mutations in the pro-
tein-coding region (data not shown). However, the top GWAS hit
(rs1561570) was found to be a strong expression quantitative
trait locus (eQTL) in human monocytes (Zeller et al., 2010) and
in peripheral blood mononuclear cells (Westra et al., 2013) with
substantially reduced levels of OPTN mRNA expression in car-
riers of the PDB-predisposing ‘‘T’’ allele with an evidence of an
allele-dose effect (Figure 1). These observations indicate that
susceptibility to PDB is associated with reduced expression of
OPTN and raise the possibility that OPTNmight act as a negative
regulator of osteoclast function.
Optn Knockdown Enhances Osteoclast Differentiation
Here, we studied the expression of optineurin during osteoclast
differentiation and investigated the effects of Optn knockdown
in primary bone-marrow-derived macrophage (BMDM) cultures.
Expression of optineurin increased considerably during osteo-
clast differentiation, following stimulation of the cultures with
macrophage colony-stimulating factor (M-CSF) and receptorthors
Figure 1. The Paget’s-Disease-Associated SNP rs1561570 Is a
Strong eQTL in Human Monocytes
OPTN gene expression levels are shown in relation to rs1561570 genotype in
human monocytes. The Paget’s disease risk allele ‘‘T’’ is associated with
reduced OPTN gene expression. Data are shown as mean ± SEM; n indicates
the number of subjects in each genotype group. Data were extracted from
(Zeller et al., 2010).activator of NF-kB ligand (RANKL) (Figure 2A). Knockdown of op-
tineurin by small hairpin RNA (shRNA) in M-CSF- and RANKL-
stimulated BMDMs significantly increased osteoclast numbers
and size when compared with a non-targeting shRNA control
(Figures 2B and 2C). Overexpression of Optn in RAW 264 cells
resulted in a substantial reduction in the number and size ofmulti-
nucleated TRAP+ cells formed upon stimulation with RANKL
(Figure S1). These experiments illustrate that optineurin acts as
a negative regulator of osteoclast differentiation in vitro.
Loss of Optn Function Induces Bone Turnover In Vivo
To investigate the effects of Optn on osteoclast activity and bone
remodelling in vivo, we conducted skeletal phenotyping of mice
homozygous for a D-to-N amino acid substitution at codon 477
of the optineurin protein (OptnD477N/D477N). This is a loss-of-func-
tion mutation that encodes a protein that is unable to bind to
Lys63-linked ubiquitin chains (Gleason et al., 2011). Bone
marrowmacrophage cultures fromOptnD477N/D477Nmice formed
significantly more osteoclasts than those from wild-type (WT) lit-
termates and the number of hypernucleated osteoclasts was
significantly increased (Figure 3A), replicating exactly the obser-
vations in WT cultures subjected to shRNA Optn knockdown
(Figure 2C). To investigate if Optn affects osteoblast differentia-
tion and/or function, we performed an in vitro bone nodule assay
and osteoblast-osteoclast co-culture assays. There was no dif-
ference between OptnD477N/D477N and WT mice in the ability of
calvarial osteoblasts to form bone nodules in vitro (Figure 3B).
However, osteoblast-osteoclast co-culture assays showed that
osteoblasts from OptnD477N/D477N mice had reduced ability to
support osteoclast differentiation when compared to WT osteo-
blast cultures (Figure 3C). In contrast, and consistent with bone
marrow culture data presented in Figure 3A, osteoclast precur-
sor cells derived from OptnD477N/D477N mice showed enhanced
sensitivity to osteoblast stimulation that appears to compensate
for the reduction in the ability of mutant osteoblast to support
osteoclast differentiation (Figure 3C).
Quantitative bone histomorphometry showed that
OptnD477N/D477N mice had significantly increased number of os-Cell Repteoclasts per bone surface (Oc.N/BS) and resorption surfaces
(Oc.S/BS) as compared with WT (Figure 3D). Indices of bone
formation (osteoid surface per bone surface [OS/BS], osteoid
volume per bone volume [OV/BV], and mineral apposition rate
[MAR]) were also significantly higher in OptnD477N/D477N mice
(Figures 3E and 3F), and there was a non-significant trend (p =
0.08) for an increase in bone formation rate (BFR/BS). These
observations illustrate that optineurin negatively regulates oste-
oclast activity both in vitro and in vivo. The lack of an effect on
osteoblast differentiation in vitro suggests that the increased
bone formation we observed in OptnD477N/D477N in vivo was
most probably secondary to the increase in bone resorption,
as occurs in humans with PDB (Ralston et al., 2008). Since
PDB is also characterized by the development of focal osteolytic
lesions that predominantly affect older people, we performed
further skeletal phenotyping of OptnD477N/D477N mice to investi-
gate bone mass and bone structure and to look for evidence of
focal osteolytic lesions in aged mice using micro-computed
tomography (micro-CT) scanning of lower limbs. There was no
difference between genotypes in BV/TV, trabecular number, or
structure in young mice (Figures S2A and S2B). However, anal-
ysis of older mice aged between 8 and 18 months revealed
evidence of a focal osteolytic lesion in the left femur in one
OptnD477N/D477N mutant mouse aged 15 months (Figure 3G; Ta-
ble S1). We then investigated the presence of bone lesions in
another loss-of-function mouse model in which the C-terminal
polyubiquitin-binding domain of Optn has been deleted, result-
ing in a truncated protein with low expression (OptnDEx12/DEx12).
Analysis of the hindlimbs of OptnDEx12/DEx12 mice (n = 8) by mi-
cro-CT showed no Paget’s-disease-like lesions (Table S1).
These observations illustrate that while the D477N loss-of-func-
tion mutation in Optn increases bone turnover, this does not
result in net bone loss, presumably because the increase in
bone resorption is coupled with that of bone formation. The
development of a focal osteolytic lesion in one OptnD477N/D477N
mutant mouse (10% of mice aged R15 months), but not in
OptnDEx12/DEx12, supports the hypothesis that loss of function
in optineurin can lead to a PDB-like phenotype while illustrating
that additional factors must also be present for focal osteolytic
lesions to become fully penetrant.
Optn Regulates Osteoclast Differentiation by
Modulating NF-kB and Interferon Signaling
Controlled RANKL-induced NF-kB activation is essential for
osteoclast differentiation and function and for the maintenance
of normal bone turnover. Previous studies have suggested
OPTN as a negative regulator of TNF-a-induced NF-kB activa-
tion in immune cells (Maruyama et al., 2010; Nagabhushana
et al., 2011; Sudhakar et al., 2009; Zhu et al., 2007), but its role
in RANKL-induced NF-kB activation is yet unknown. In order
to investigate the effects of Optn on intracellular signaling in os-
teoclasts, we studied RANKL-induced NF-kB activation during
osteoclast differentiation in cultures from OptnD477N/D477N mice
as well as in Optn knockdown cultures. We found no difference
in RANKL-induced NFkB activation, as measured by phosphor-
ylation of IkBa, in BMDMs from D477N mutant mice compared
with WT (Figure 4A). However, following RANKL stimulation,
there was a progressive increase in NF-kB activation that wasorts 13, 1096–1102, November 10, 2015 ª2015 The Authors 1097
Figure 2. Optn Knockdown in Mouse Bone-Marrow-Derived Mac-
rophages Enhances Osteoclast Differentiation
(A) Immunoblot showing the expression of Optn during osteoclast differenti-
ation. BMDMswere stimulatedwithM-CSF (25 ng/ml) and RANKL (100 ng/ml),
and Optn expression was examined in cell lysate at the indicated time points.
Anti-b-actin was used as loading control.
(B) Immunoblot showing Optn knockdown in BMDMs. Cells were transduced
with lentiviral particles expressing shRNA targeting the Optn gene or non-
targeting control (NTC).
(C) Enhanced osteoclast differentiation in Optn knockdown BMDM.
Optn-depleted or NTC cells were stimulated with M-CSF (25 ng/ml) and
RANKL (indicated concentrations), and TRAP+ multinucleated cells (MNC)
were counted and shown as mean ± SEM from three independent experi-
ments.
1098 Cell Reports 13, 1096–1102, November 10, 2015 ª2015 The Ausignificantly greater in cultures from OptnD477N/D477N as
compared with WT mice, with a maximal effect at 3 days (Fig-
ure 4B). Similar findings were observed in Optn knockdown
cultures in which reduced expression of Optn by knockdown
resulted in enhanced NF-kB activity after RANKL stimulation
(Figure 2D). These findings indicate that the inhibitory effects of
Optn become most apparent as osteoclast differentiation pro-
ceeds and is consistent with the observation that Optn levels
increase substantially during osteoclast differentiation (Fig-
ure 2A). A similar mechanism has previously been reported in
Cyld null mice, which show no abnormalities of RANKL-induced
NF-kB activation in BMDMs but show enhanced NF-kB activa-
tion as osteoclast differentiation proceeds (Jin et al., 2008).
Previous studies have shown that the deubiquitinase enzyme
CYLD plays an important negative regulatory role in NF-kB
signaling in osteoclasts by interacting with p62 and TRAF6 (Jin
et al., 2008). It has also been reported that optineurin is required
for CYLD-dependent inhibition of NF-kB activation in immune
cells (Nagabhushana et al., 2011). Since the D477N mutation is
located in the region that binds to CYLD (Nagabhushana et al.,
2011), we studied the effects of the mutant protein on CYLD
binding by immunoprecipitation in osteoclasts. This confirmed
that the D477N Optn variant had an impaired ability to bind
CYLD compared with WT Optn (Figure 4C), indicating that the
inhibitory effect of Optn on osteoclast is mediated, in part, by a
CYLD-dependent pathway. It has previously been shown that
the expression of mutant OptnD477N protein was higher than
that of WT in multiple tissues including BMDMs (Gleason et al.,
2011). In line with these findings, we also observed that the
expression of the mutant OptnD477N protein during osteoclast
differentiation was higher than that of the WT (Figures 4C and
4E). This difference was more noticeable from day 3 post-
RANKL stimulation (Figure 4E), possibly due to increased
NF-kB activity, since a putative NF-kB binding site has been re-
ported in Optn promoter (Sudhakar et al., 2009). However, the
increased levels of expression of the mutant OptnD477N protein
were clearly not sufficient to compensate for its reduced ability
to suppress NF-kB activity and osteoclast differentiation.
Studies have shown that while RANKL stimulates osteoclast
activity, it also initiates a negative auto-regulatory effect on oste-
oclasts through induction of interferon beta (IFN-b) expression
(Takayanagi et al., 2002; Hayashi et al., 2002), which has an
inhibitory effect on osteoclast by interfering with RANKL-
induced expression of c-Fos (Takayanagi et al., 2002). Since pre-
vious studies have shown that optineurin is involved in IFN-b
signaling in immune cells (Gleason et al., 2011; Munitic et al.,
2013), we investigated if Optn plays a role in this negative regu-
latory loop in osteoclast by studying the expression of IFN-b and
c-Fos in both WT and OptnD477N/D477N mutant cells. We found(D) RANKL-induced NF-kB activation during osteoclast differentiation. Optn-
depleted or NTC cells were transduced with lentiviral particles expressing an
NF-kB luciferase reporter followed by stimulation withM-CSF and RANKL, and
reporter activity wasmeasured at the indicated time points. Values are mean ±
SEM from two independent experiments presented as%ofNTC-shRNA. Blots
and pictures are representative of three independent experiments. *p < 0.05;
**p < 0.01 compared to NTC.
See also Figure S1.
thors
Figure 3. BonePhenotypeofOptnD477N/D477N
Mice
(A) Enhanced osteoclast differentiation in
OptnD477N/D477N bone-marrow-derived macro-
phages (BMDMs). WT and mutant BMDMs were
stimulated with M-CSF and RANKL, and the
number of TRAP +multinucleated cells (MNC) was
counted and shown as mean ± SEM from three
independent experiments.
(B) Bone nodule formation assessed by alizarin red
staining in neonatal calvarial osteoblasts from WT
andOptnD477N/D477Nmice. Alizarin red values were
corrected for viable cell count, and values repre-
sent mean ± SEM from three independent experi-
ments.
(C) Osteoblast-osteoclast co-culture assay. Cal-
varial osteoblasts (OBs) were isolated fromWT and
OptnD477N/D477N mice and co-cultured with bone
marrow osteoclast precursor cells (OCPs), and the
number of TRAP+ MNC were counted. Values are
mean ± SEM from two independent experiments
presented as percentage of WT/WT combination.
(D–F) Histomorphometrical analysis of trabecular
bone showing enhanced bone turnover in
OptnD477N/D477N mice. Representative images of
proximal tibial metaphysis stained with TRAP (D),
Von Kossa (E), or calcein double labeling (F).
Graphs on the right represent comparison of bone
resorption indices (osteoclast number per bone
surface [Oc.N/BS] and osteoclast surface per
bone surface [Oc.S/BS]), bone formation indices
(osteoid surface per bone surface [OS/BS] and
osteoid volume per bone volume [OV/BV]), or
dynamic bone formation indices (mineral apposi-
tion rate [MAR] and bone formation rate per bone
surface [BFR/BS]) between WT and mutant mice.
Data are shown as mean ± SEM from seven to
eight animals per group.
(G) PDB-like lesions observed in the left femur of a
15-month-old OptnD477N/D477N mouse. Micro-CT
images showing osteolytic bone lesion within the
cortex and histological analysis showing enhanced
osteoclastogenesis in the affected region. *p <
0.05, **p < 0.01; n.s., not significant compared
to WT.
See also Figure S2 and Table S1.that RANKL induced the expression of IFNb in both WT and
OptnD477N/D477N mutant cells, but the expression levels were
significantly lower in mutant cells compared to those observed
in WT (Figure 4D). Additionally, c-Fos expression during later
stages of osteoclast differentiation (3 days post-RANKL stimula-
tion onward) from OptnD477N/D477N mice was higher than that
observed in WT (Figure 4E). These data suggest that in addition
to its inhibitory effect on NF-kB signaling, Optnmay also exert an
inhibitory role on osteoclast differentiation by modulating the
IFN-b signaling pathway.
Coupling between bone formation by osteoblasts and
bone resorption by osteoclasts is a complex mechanism, but
it is well known that osteoblasts produce many pro-osteo-
clastogenic cytokines to regulate osteoclast function such
as TNFSF11 (RANKL) and IL-6. Expression of these two cyto-Cell Repkines in osteoblast cultures derived from OptnD477N/D477N
mice was significantly lower than that observed in WT cul-
tures, which is consistent with the reduced ability of mutant
osteoblast to support osteoclast differentiation (Figures 4F
and 4G).
Conclusions
In conclusion, we have demonstrated that reduced expression
or loss of Optn function in mice leads to enhanced osteoclast
differentiation, identifying Optn as a negative regulator of osteo-
clast differentiation. The underlying mechanisms are complex
but involve RANKL-induced NF-kB activation, an interaction
with CYLD, and regulation of IFN-b signaling with regulatory
effects that are cell-type specific, dependent on its expres-
sion level and on its ability to bind polyubiquitin. Our dataorts 13, 1096–1102, November 10, 2015 ª2015 The Authors 1099
Figure 4. RANKL-Induced NF-kB Activation and IFN-b Induction in OptnD477N/D477N Mice
(A) BMDMs from WT or mutant mice were stimulated with RANKL (100 ng/ml) and NF-kB activation was assessed by immunoblotting of pIkBa at the indicated
time points.
(B) RANKL-induced NF-kB activation during osteoclast differentiation fromWT and mutant mice. BMDMs were transduced with lentiviral particles expressing an
NF-kB luciferase reporter followed by stimulation with M-CSF and RANKL, and reporter activity was measured at the indicated time points.
(C) Reduced binding of mutant OptnD477N protein to Cyld in osteoclasts. BMDMs from WT and mutant mice were stimulated with M-CSF and RANKL for 5 days
and Optn was immunoprecipitated (IP) from cell lysate, and the presence of Cyld and Optn in the immunoprecipitates was analyzed by immunoblotting (IB). The
graph to the right represents band quantification by densitometry of the amount of Cyld in the immunoprecipitates corrected for Optn.
(D) IFN-bmRNA expression in response to RANKL stimulation of WT and OptnD477N/D477N osteoclast precursors. Cells were stimulated with RANKL (100 ng/ml),
and total RNA was extracted at the indicated time points and analyzed by quantitative real time PCR for IFN-b mRNA levels.
(E) Optn and c-Fos expression during osteoclast differentiation in WT and OptnD477N/D477N mice. BMDMs were stimulated with M-CSF (25 ng/ml) and RANKL
(100 ng/ml) and expression was assessed by immunoblotting at the indicated time points; lane 1 (WT-0) was rearranged to ease comparison.
(F andG) Expression of TNFSF11 (F) and IL6 (G) during osteoblast differentiation inWT andOptnD477N/D477Nmice. Calvarial osteoblasts were isolated and cultured
in osteogenic media and mRNA expression was analyzed by quantitative real-time PCR at the indicated time points.
Values in all graphs are mean ± SEM from three independent experiments presented as percentage of WT. mRNA levels were normalized for 18 s rRNA
expression, and results are presented as percentage of WT values. *p < 0.05, **p < 0.01; n.s., not significant compared to WT.suggest that the common genetic variant rs1561570 at the
OPTN locus increases susceptibility to PDB by reducing levels
of OPTN expression, probably leading to enhanced osteoclast
differentiation.
EXPERIMENTAL PROCEDURES
Reagents
Details of the materials and reagents can be found in Supplemental Experi-
mental Procedures.1100 Cell Reports 13, 1096–1102, November 10, 2015 ª2015 The AuMice
The generation of OptnD477N/D477N knockin mice was described previously
(Gleason et al., 2011). To generate OptnDEx12/DEx12, the OptnD477N/D477N mice
were first crossed to Flpe/ mice to remove the Flpe transgene, and these
mice were then crossed to Bal-1 Cre mice to delete exon 12. All experiments
were performed according to institutional, national, and European animal
regulations.
Micro-Computed Tomography Analysis
Micro-CT analysis was performed using an in vivo Skyscan 1076 or an ex vivo
Skyscan 1172 system. Live animals were scanned on the in vivo scannerthors
looking for the development of PDB-like lesions as previously described (Dar-
oszewska et al., 2011), and those showing evidence of lesions were further
analyzed on the ex vivo scanner and then subjected to histological analysis
as described below. Image reconstruction was performed using the Skyscan
NRecon package and trabecular bone parameters measured using Skyscan
CTAn software.
Histomorphometrical Analysis
Animals received two intraperitoneal injections of calcein 3 days apart before
being culled. The hindlimbs were fixed for 24 hr in 4% formalin-buffered saline
and stored in 70% ethanol prior to embedding in methyl methacrylate. The
bones were processed for static and dynamic histomorphometry according
to standard techniques. Sections were stained for tartrate-resistant acid phos-
phatase (TRAP) with aniline blue counterstain to visualize osteoclasts and
osteoid analysis was done after Von Kossa staining with Van Gieson counter-
staining according to standard protocols as previously described (Erben and
Glo¨smann, 2012). Histomorphometry was performed using custom-built soft-
ware and followed standardized nomenclature and recommendations (Demp-
ster et al., 2013).
Osteoclast Culture
Bonemarrow cells were isolated from the long bones of 4-month-old mice and
cultured for 48 hr in the presence of M-CSF (100 ng/ml) to generate BMDMs.
Adherent cells were reseeded and stimulated with M-CSF (25 ng/ml) and
RANKL for 5 days until osteoclasts were formed. Cells were fixed with 4%
(v/v) formaldehyde in PBS and stained for TRAP. TRAP-positive multinucle-
ated osteoclasts (more than three nuclei) were counted, and numbers were
compared to the WT control. For the NF-kB activation assay, BMDMs were
generated as described above and incubated under standard conditions
for 24 hr. Cells were serum starved for 1 hr followed by stimulation with
100 ng/ml RANKL. Cell lysates were collected at different time points and as-
sayed by immunoblotting. For the NF-kB luciferase reporter assay, BMDMs
were transduced with lentiviral NF-kB luciferase reporter for 2 days followed
by selection for 48 hr using puromycin (5 mg/ml). The cells were then plated
in 96-well plates and luciferase activity was measured with a SteadyGlo-lucif-
erase reporter assay system at the indicated time points following M-CSF
(25 ng/ml) and RANKL stimulation (100 ng/ml) using a Bio-Tek Synergy HT
plate reader. The medium used was complete minimum essential medium
alpha modification (aMEM), and all cultures were incubated under standard
conditions of 5% CO2 and 37
C in a humidified atmosphere.
Osteoblast Culture and Bone Nodule Assay
Osteoblasts were isolated from the calvarial bones of 2-day-old mice by
sequential collagenase/EDTA digestion and cultured in complete aMEM
medium. On reaching confluence, cells were detached with trypsin, re-plated
in 12-well plates at a density of 1 3 105 cells/well, and cultured in osteogenic
medium (complete aMEM supplemented with 50 mg/ml vitamin C and 3 mM
b-glycerophosphate). The medium was replaced three times per week, and
cultures were continued for up to 21 days. Mineralized nodules were detected
using alizarin red staining, and bone nodule formation was quantified by de-
staining the cultures in 10% (w/v) cetylpyridinium chloride and dissolving the
stain in 10 mM sodium phosphate (pH 7.0). The absorbance of the extracted
stain was then measured at 562 nm and compared to an alizarin red standard
curve. Alizarin red values were corrected for viable cell number as determined
by the alamar blue assay.
Optn Knockdown
Bone marrow cells from WT mice were isolated and cultured for 48 hr in com-
plete aMEM supplemented with M-CSF (100 ng/ml). The adherent BMDMs
were then transduced with either lentiviral particles containing shRNA tar-
geted against the Optn gene or negative control particles (non-targeting lenti-
viral particles). Transduced cells were selected for 48 hr using puromycin
(5 mg/ml). Optn-depleted BMDMs were then plated in 96-well plates and stim-
ulated with M-CSF (25 ng/ml) and RANKL (25 or 50 ng/ml) until osteoclasts
were formed. TRAP-positive multinucleated osteoclasts were counted and
numbers were compared to the non-targeted negative control. Optn-depletion
was confirmed at all stages of osteoclast differentiation by immunoblotting.Cell RepStatistical Analyses
Values in the graphs indicate group means ± SEM, as indicated in the legends.
Comparisons between groups were performed by two-tailed t test. p < 0.05
was considered to indicate statistical significance. Experiments were per-
formed as independent replicates as indicated in figure legends.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
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